Skip to main content
SpringerLink
Log in

Tumoren des lymphatischen Systems

  • Chapter
  • First Online:
Strahlentherapie

  • 9009 Accesses

Zusammenfassung

Der M. Hodgkin ist eine seltene Erkrankung, die Häufigkeit beträgt etwa 0,7 % aller bösartigen Erkrankungen und die Todesrate liegt bei etwa 0,3 % aller Todesfälle durch Malignome. Die Morbidität liegt bei etwa 3,1 pro 100.000 Einwohner, Männer sind etwas häufiger betroffen als Frauen (1,1:1), die Altersverteilung weist 2 Gipfel auf, zwischen 25 und 35 Jahren und zwischen 60 und 75 Jahren.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

Zu Morbus Hodgkin

  • Aleman BM, Raemaekers JM, Tirelli U et al. (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348 (24) 2396–2406

    PubMed  Google Scholar 

  • Aleman BM, Raemaekers JM, Tomiŝiĉ R et al. (2007) Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 67 (1) 19–30

    PubMed  Google Scholar 

  • Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 (5): 1878–1886

    PubMed  CAS  Google Scholar 

  • Anderson H, Crowther D, Deakin DP, Ryder WDJ, Radford JA (1991) A randomized study of adjuvant MVPP chemotherapy after mentle radiotherapy in pathological staged IA-IIB Hodgkin’s disease: 10-year follow-up. Ann Oncol 2:49

    PubMed  Google Scholar 

  • Andrieu J, Coscas Y, Kramer P et al. (1985) Chemotherapy plus radiotherapy in clinical stage IA-IIIB Hodgkin’s disease. Results of the H77 trial (1977–1980). In: Cavalli F, Bonadonna G, Rosencweig M (eds) Malignant lymphomas and Hodgkin’s disease: experimental and therapeutic advances. Martinus Nijhoff, Dordrecht, pp 353–361

    Google Scholar 

  • Angel CA, Warford A, Campbell AC, Pringle JH, Lauder I (1987) The immunohistology of Hodgkin’s disease – Reed-Sternberg cells and their variants. J Pathol 153:21–30

    PubMed  CAS  Google Scholar 

  • Ballova V, Rüffer JU, Haverkamp H et al. (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16 (1):124–131

    PubMed  CAS  Google Scholar 

  • Bar-Shalom R, Israel O, Harim N et al. (1996) Diffuse lung uptake of Ga-67 after treatment of lymphoma: Is it of clinical importance? Radiology 199:473–476

    PubMed  CAS  Google Scholar 

  • Bartlett N, Rosenberg S, Hoppe R, Hancock S, Horning S (1995) Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 13:1080–1088

    PubMed  CAS  Google Scholar 

  • Barton M, Boyages J, Crennan E et al. (1995) Radiation therapy for early stage Hodgkin’s disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group. Int J Radiat Oncol Biol Phys 31:227–236

    PubMed  CAS  Google Scholar 

  • Bates N, Williams M, Bessell E, Hudson G, Hudson B (1994) Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved field radiotherapy and clinical stage IA and IIA Hodgkin’s disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 12:288–296

    PubMed  CAS  Google Scholar 

  • Bathia S, Robinson LL, Oberlin O et al. (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 334:745–751

    Google Scholar 

  • Bennett MH, MacLennan KA, Hudson BV, Hudson GV (1990) The clinical and prognostic relevance of histopathologic classification in Hodgkin’s disease. Prog Surg Pathol 10:127

    Google Scholar 

  • Bierman P, Bagin R, Jagannath S et al. (1993) High dose chemotherapy followed by autologous hematopoetic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 4:767

    PubMed  CAS  Google Scholar 

  • Biti G, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378–382

    PubMed  CAS  Google Scholar 

  • Biti G, Celai E, Magrini SM, Papi MG, Ponticelli P, Boddi V (1994) Second solid tumors and leukemia after treatment for Hodgkin’s disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 29:25–31

    PubMed  CAS  Google Scholar 

  • Bjorkholm M, Holm M, Mellstedt H (1977) Immunologic profile in patients with cured Hodgkin’s disease. Scand J Haematol 19:361–368

    Google Scholar 

  • Bloomfield C, Pajak T, Glicksman A et al. (1982) Chemotherapy and combined modality therapy for Hodgkin’s disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep 66:835–846

    PubMed  CAS  Google Scholar 

  • Bonadonna G (1982) Chemotherapy strategies to improve the control of Hodgkin’s disease. The Richard and Hina Rosenthal Foundation Award Lecture. Cancer Res 42:4309–4320

    PubMed  CAS  Google Scholar 

  • Bonadonna G, Zucali R, Monfardini S, Lena MD, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycine, bleomycine, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259

    PubMed  CAS  Google Scholar 

  • Borchmann P, Haverkamp H, Diehl V et al. (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group Nov 10;29(32):4234–4242

    Google Scholar 

  • Brizel DM, Gockerman JP, Crawford J et al. (1994) A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin’s disease. Cancer 74:159–163

    PubMed  CAS  Google Scholar 

  • Brown A, Urie M, Barest G et al. (1991) Three-dimensional photon treatment planning for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 21:205–215

    PubMed  CAS  Google Scholar 

  • Canellos G, Young RC, DeVita VD (1972) Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharm Ther 13:750

    Google Scholar 

  • Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478

    PubMed  CAS  Google Scholar 

  • Canellos GP, Horvich A (1999) Management of recurrent Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 507–519

    Google Scholar 

  • Carbone PP, Kaplan H, Musshoff K (1971) Report of the committee on Hodgkin’s disease staging. Cancer Res 31:1860–1861

    PubMed  CAS  Google Scholar 

  • Carde P, Burgers JM, Henry-Amar M et al. (1988) Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239–252

    PubMed  CAS  Google Scholar 

  • Carde P, Hagenbeek A, Hayat M et al. (1993) Clinical staging versus laparotomy and combine modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258–2272

    PubMed  CAS  Google Scholar 

  • Carde P, Noordijk E, Hagenbeek A et al. (1997) Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 16:13 (abst)

    Google Scholar 

  • Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s disease – an analysis of technique, tumor eradication, and complications. Cancer 37:2813–2825

    PubMed  CAS  Google Scholar 

  • Castellino R, Dunnick N, Goffinet D et al. (1983) Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 1:532

    PubMed  CAS  Google Scholar 

  • Coia L, Hanks G (1988) Complications from large field intermediate dose infradiaphragmatic radiation: An analysis of the patterns of care outcome studies for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 15:29–35

    PubMed  CAS  Google Scholar 

  • Coltman C, Myers J, Montague E et al. (1982) The role of combined radiotherapy and chemotherapy in the primary management of Hodgkin’s disease. In: Rosenberg S, Kaplan H (eds) Malignant lymphomas: etiology, immunology, pathology, treatment. Academic Press, pp 523–536

    Google Scholar 

  • Connors JM, Yahalom J, Noordijk EM (1999) Principles of combined-modality therapy in Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 395–407

    Google Scholar 

  • Cosset J, Ferme C, Noordijk E (1996) Combined modality therapy for poor prognosis stages I and II Hodgkin’s disease. Semin Radiat Oncol 6:185

    PubMed  Google Scholar 

  • Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM (1987) Stage I to IIB Hodgkin’s disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 5:1041–1049

    PubMed  CAS  Google Scholar 

  • Davis AB (1911) Report of a case of Hodgkin’s disease complicated by pregnancy. Bull Lying-in Hosp NY 7:151–158

    Google Scholar 

  • De Bruin ML, Sparidans J, van’t Veer MB, et al. (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246

    PubMed  Google Scholar 

  • DeVita VT, Simon RM, Hubbard SM et al. (1980) Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients in the National Cancer Institute. Ann Intern Med 92:587–595

    PubMed  Google Scholar 

  • Diehl V, Pfreundschuh M, Loeffler M et al. (1987) Therapiestudien der Deutschen Hodgkin Studiengruppe. Zwischenergebnisse der Studienprotokolle HD1, HD2 und HD3. Onkologie 10:62–66

    PubMed  CAS  Google Scholar 

  • Diehl V, Loeffler M, Pfreundschuh M et al. (1995) Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin’s disease. German Hodgkin Study Group (GHSG). Ann Oncol 6:901–910

    PubMed  CAS  Google Scholar 

  • Diehl V, Sieber M, Rüffer U et al. (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s Lymphoma Group. Ann Oncol 8:143–148

    PubMed  CAS  Google Scholar 

  • Diehl V, Franklin J et al. (1998 a) BEACOPP: A new regimen for advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 9 (Suppl 5):67–71

    Google Scholar 

  • Diehl V, Franklin J, Hasenclever D et al. (1998 b) BEACOPP, a new dose-escalated and accelerated regimen, at least as effective as COPP/ABVD in patients with advanced stage Hodgkin lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 16:3810–3821

    PubMed  CAS  Google Scholar 

  • Diehl V, Sextro M, Franklin J et al. (1999) Clinical presentation, course, and prognosis factors in lymphocyte-predominant Hodgkin’s disease: a report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s disease. J Clin Oncol 17:776

    PubMed  CAS  Google Scholar 

  • Diehl V, Franklin J, Pfreundschuh M, et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 348 (24) 2386–2395

    PubMed  CAS  Google Scholar 

  • Dühmke E, Diehl V, Loeffler M et al. (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended-field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310

    PubMed  Google Scholar 

  • Dühmke E, Franklin J, Pfreundschuh M et al. (2001) Low dose radiation is sufficient for noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914

    PubMed  Google Scholar 

  • Dunn J (1994) Doxorubicin-induced cardiomyopathy. J Pediatr Oncol Nurs 11:152–160

    PubMed  CAS  Google Scholar 

  • Dutcher J, Wiernik P (1985) Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Dev Oncol 32:317–327

    Google Scholar 

  • Easson E, Russel M (1963) The cure of Hodgkin’s disease. Br J Med 1:1704–1707

    CAS  Google Scholar 

  • Eich HT, Diehl V, Goergen H, et al. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. J Clin Oncol 2010: in press

    Google Scholar 

  • Eich HT, Engenhart-Cabillic R, Hansemann K, et al. (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin´s lymphoma – an analysis of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2008; 71(5):1419–1424.

    PubMed  Google Scholar 

  • Eich HT, Gossmann A, Engert A, et al. (2007) A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma - analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69 (4):1187–1192.

    PubMed  Google Scholar 

  • Eich HT, Haverkamp U, Engert A et al. (2005) Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin’s Lymphoma – a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 63 (3):860–865

    PubMed  Google Scholar 

  • Eich HT, Müller R-P (2005) The radiotherapy reference panel - experiences and results of the German Hodgkin Study Group (GHSG). Eur J Haematol 75 (Suppl 66) 98–105

    Google Scholar 

  • Eich HT, Müller R-P (2007) Current role and future developments of radiotherapy in early-stage favourable Hodgkin’s lymphoma. Strahlenther Onkol (Sondernr 2) 16–18

    Google Scholar 

  • Eich HT, Müller R-P, Engenhart-Cabillic R, et al. (2008) Involved Node Radiotherapy in early-stage Hodgkin’s Lymphoma – Definition and Guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol; 184 (8):406–410

    PubMed  Google Scholar 

  • Eich HT, Müller RP, Schneeweiss A et al. (2004 a) Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 58:805–808

    PubMed  Google Scholar 

  • Eich HT, Staar S, Gossmann A et al. (2004b) Centralized radiation oncological review of cross-sectional imaging of Hodgkin’s disease leads to significant changes of the required involved field – results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 58:1121–1127

    Google Scholar 

  • Eich HT, Zimmermann C, Müller R-P. 2010)Involved-Node-Radiotherapie in frühen Stadien des Hodgkin-Lymphoms. Onkologe 2010;16:35–40

    Google Scholar 

  • Ekstrand BC, Lucas JB, Horwitz SM et al. (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101 (11):4285–4289

    PubMed  CAS  Google Scholar 

  • Engert A, Schiller P, Josting A, et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma Study Group. J Clin Oncol 21 (19):3601–3608

    PubMed  Google Scholar 

  • Engert A, Ballova V, Haverkamp H et al. (2005) Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol 23 (22):5052–5060

    PubMed  Google Scholar 

  • Engert A, Franklin J, Eich HT et al. (2007) Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early-favourable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25 (23):3495–3502

    PubMed  CAS  Google Scholar 

  • Engert A, Diehl V, Franklin J al. (2009) BEACOPPescalated in the treatment of patients with advanced-stage Hodgkin Lymphoma: 10 years follow-up of the GHSG HD9 study. J Clin Oncol. Sep 20;27(27):4548–4554

    PubMed  Google Scholar 

  • Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al. (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652

    PubMed  CAS  Google Scholar 

  • Engert A, Haverkamp H, Kobe C et al. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet May 12;379(9828):1791–1799

    Google Scholar 

  • Erdkamp FL, Breed WP, Bosch LJ, Wijnen JT, Blijham GB (1992) Hodgkin’s disease in the elderly. Cancer 70:830

    PubMed  CAS  Google Scholar 

  • Fabian CJ, Mansfield CM, Dahlberg S et al. (1994) Low-dose involved-field radiation after chemotherapy in advanced Hodgkin’s disease. Ann Intern Med 120:903–912

    PubMed  CAS  Google Scholar 

  • Fermé C, Eghbali H, Meerwaldt JH, et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med.357(19):1916–1927

    PubMed  Google Scholar 

  • Fletcher GH, Shukovsky LJ (1975) The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 56:383–400

    PubMed  CAS  Google Scholar 

  • Gallamini A, Hutchings M, Rigacci L et al. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (24):3746–3752

    PubMed  CAS  Google Scholar 

  • Gehan E, Sullivan M, Fuller L et al. (1990) The intergroup Hodgkin’s disease study in children. Cancer 65:1429–1437

    PubMed  CAS  Google Scholar 

  • Gelb AB, VandeRijn M, Warnke RA (1996) Pregnancy-associated lymphomas. A clinico-patologic study. Cancer 78:304

    PubMed  CAS  Google Scholar 

  • Gilbert R (1925) La roentgentherapie de la granulomatose maligne. J Radiol Electrol 9:509–514

    Google Scholar 

  • Gilbert R (1939) Radiotherapy in Hodgkin’s disease (malignant granulomatosis); anatomic and clinical foundations; governing principles, results. Am J Roentgenol 41:198–241

    Google Scholar 

  • Gilbert R, Babaiantz L (1931) Notre methode de roentgentherapie de la lymphogranulomatose (Hodgkin); resultats eloignes. Acta Radiol 12:523–529

    Google Scholar 

  • Ginzton E, Mallory K, Kaplan H (1957) The Stanford medical linear accelerator I: design and development. Stanford Med Bull 15:123–140

    PubMed  CAS  Google Scholar 

  • Girinsky T, van der Maazen R, Specht L et al. (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79 (3) 270–277

    PubMed  Google Scholar 

  • Glaser S, Lin R, Stewart S et al. (1997) Eppstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer 70:375

    PubMed  CAS  Google Scholar 

  • Glatstein E, Guernsey J, Rosenberg S, Kaplan H (1969) The value of laparotomy and splenectomy in staging of Hodgkin’s disease. Cancer 24:709–718

    PubMed  CAS  Google Scholar 

  • Goldie JH, Coldmann AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatm Rep 63:1727–1733

    CAS  Google Scholar 

  • Gomez G, Sullivan M, Fuller L et al. (1984) Large mediastinal mass in Hodgkin’s disease. Results of two treatment modalities. Am J Clin Oncol 6:65–73

    Google Scholar 

  • Gross NJ (1977) Pulmonary effects of radiation therapy. Ann Intern Med 86:81–92

    PubMed  CAS  Google Scholar 

  • Hagemeister F, Fuller L, Velasquez W et al. (1982) Stage I and II Hodgkin’s disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 66: 789–798

    PubMed  CAS  Google Scholar 

  • Hancock S, Hoppe R, Horning S (1988) Intercurrent death after Hodgkin’s disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 109:183

    PubMed  CAS  Google Scholar 

  • Hancock S, Cox R, Dougall IM (1991) Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 325:599–605

    PubMed  CAS  Google Scholar 

  • Hancock S, Tucker MA, Hoppe RT (1993 a) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31

    PubMed  CAS  Google Scholar 

  • Hancock SL, Tucker MA, Hoppe RT (1993 b) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949–1955

    PubMed  CAS  Google Scholar 

  • Hancock SL, Donaldson SS, Hoppe RT (1993 c) Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 7:1208–1215

    Google Scholar 

  • Hancock S, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6:225–242

    PubMed  Google Scholar 

  • Hanks G, Kinzie J, White R, Herring D, Kramer S (1983) Patterns of care outcome studies: Results of national practice in Hodgkin’s disease. Cancer 51:569–573

    PubMed  CAS  Google Scholar 

  • Hansmann ML, Wacker HH, Radzun HJ (1986) Paragranuloma is a variant of Hodgkin’s disease with predominance of B-cells. Virchows Arch A 409:171–181

    CAS  Google Scholar 

  • Harris NL, Jaffe ES, Stein H (1994) European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361

    PubMed  CAS  Google Scholar 

  • Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. Ann Oncol 7 (Suppl 4):95–98

    PubMed  Google Scholar 

  • Haybittle J, Easterling M, Bennett M et al. (1985) Review of British National Lymphoma Investigation Studies of Hodgkin’s disease and development of prognostic index. Lancet 1:967–972

    PubMed  CAS  Google Scholar 

  • Henry-Amar M (1992) Second cancer after the treatment of Hodgkin’s disease – a report from the international Database on Hodgkin’s disease. Ann Oncol 3 (Suppl 4):117–128

    PubMed  Google Scholar 

  • Henry-Amar M, Friedman S, Hayat M et al. (1991) Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 114:361–365

    PubMed  CAS  Google Scholar 

  • Herbst C, Rehan FA, Brillant C et al. (2001) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 95 (3):494–500

    Google Scholar 

  • Hirsch A, Els NV, Straus DJ et al. (1996) Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol 14:1297–1305

    PubMed  CAS  Google Scholar 

  • Hodgkin T (1832) On some morbid experiences of the absorbent glands and spleen. Med Chir Trans 17:69–97

    Google Scholar 

  • Hoogstraten B, Holland J, Kramer S et al. (1973) Combination chemotherapy radiotherapy for stage III Hodgkin’s disease. Arch Intern Med 131:424–428

    PubMed  CAS  Google Scholar 

  • Hoppe RT (1983) The definitive management of limited and intermediate stages of Hodgkin’s disease with radiotherapy alone. In: Bennett JM (ed) Controversies in the management of lymphomas. Nijhoff, Dordrecht, pp 129–150

    Google Scholar 

  • Hoppe RT (1996) Hodgkin’s disease – the role of radiation therapy in advanced disease. Ann Oncol 7 (Suppl 4):99–103

    PubMed  Google Scholar 

  • Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I-II Hodgkin’s disease with irradiation allone or combined modality therapy: the Stanford experience. Blood 59:455–465

    PubMed  CAS  Google Scholar 

  • Hoppe R, Horning S, Hancock S, Rosenberg S (1989) Current Standford clinical trials for Hodgkin’s disease. Recent results in cancer research. Springer, Berlin Heidelberg New York Tokio

    Google Scholar 

  • Hoppe RT, Cosset JM, Santoro A, Wolf J (1999) Treatment of unfavorable prognosis stage I-II Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 459–481

    Google Scholar 

  • Horning SJ, Hoppe RT, Rosenberg SA (1984) The Stanford Hodgkin’s disease trials 1967–1983. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune & Stratton, New York

    Google Scholar 

  • Horning S, Hoppe R, Hancock S (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6:1822

    PubMed  CAS  Google Scholar 

  • Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA (1994) Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 12:297–305

    PubMed  CAS  Google Scholar 

  • Horning SJ, Bennett JM, Bartlett NL, Williams J, Neuberg D, Casileth P (1996) 12 weeks of chemotherapy stanford V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin’s disease: a limited institution ECOG pilot study. Blood 88:2681 (abst)

    Google Scholar 

  • Horning SJ, Hoppe RT, Mason J et al. (1997) Stanford-Kiaiser Permanente G1 study for clinical stage I to IIA Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736–1744

    PubMed  CAS  Google Scholar 

  • Hudson MM, Greenwald C, Thompson E (1993) Efficacy and toxicity of multiagent chemotherapy and low-dose involvedfield radiotherapy in children and adolescents with Hodgkin’s disease. J Clin Oncol 11:100–108

    PubMed  CAS  Google Scholar 

  • Hunger SP, Link MP, Donaldson SS (1994) ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience. J Clin Oncol 12:2160–2166

    PubMed  CAS  Google Scholar 

  • Hutchinson GB (1976) Survival and complications of radiotherapy following involved and extended field radiotherapy of Hodgkin’s disease stage I and II. A collaborative study. Cancer 38:288–305.

    Google Scholar 

  • Hutchinson G, Allison R, Fuller L et al. (1984) Collaborative study: radiotherapy of stage I and II Hodgkin’s disease. Cancer 54:1928–1942 alone.

    Google Scholar 

  • Hutchings M, Loft A, Hansen M, et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 107 (1):52–59

    PubMed  CAS  Google Scholar 

  • Hutchings M, Loft A, Hansen M et al. (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 78 (3):206–212

    PubMed  Google Scholar 

  • Jackson H, Parker F (1944) Hodgkin’s disease. II Pathology. N Engl J Med 231:35–44

    Google Scholar 

  • Johnson R, Thomsa L, Schneiderman M et al. (1970) Preliminary experience with total nodal irradiation in Hodgkin’s disease. Radiology 96:603–608

    PubMed  CAS  Google Scholar 

  • Josting A, Katay I, Rueffer U et al. (1998) Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289

    PubMed  CAS  Google Scholar 

  • Josting A, Rueffer U, Franklin J et al. (1999) Prognostic factors and treatment outcome in patients with primary progressive Hodgkin’s lymphoma – a report from the German Hodgkin’s Disease Study Group (GHSG). Blood 10 (Suppl 1):2299a

    Google Scholar 

  • Josting A, Reiser M, Rueffer U (2000) Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s disease – Is there a chance for cure? J Clin Oncol 18:332

    PubMed  CAS  Google Scholar 

  • Josting A, Nogova L, Franklin J et al. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s Lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 23 (7):1522–1529

    PubMed  Google Scholar 

  • Juweid ME (2006) Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 510-1:259–265

    Google Scholar 

  • Kaldor J, Day N, Bell J et al. (1992) Lung cancer following Hodgkin’s disease: a case-control study. Int J Cancer 52:677

    PubMed  CAS  Google Scholar 

  • Kaplan H (1962) The radical radiotherapy of Hodgkin’s disease. Radiology 78:553–561

    PubMed  CAS  Google Scholar 

  • Kaplan H (1966 a) Long-term results of palliative and radical radiotherapy of Hodgkin’s disease. Cancer Res 26:1250–1252

    PubMed  CAS  Google Scholar 

  • Kaplan HS (1980) Hodgkin’s disease, 2nd edn. Harvard University Press, Cambridge

    Google Scholar 

  • Kaplan HS, Rosenberg SA (1966) Extended-field radical radiotherapy in advanced Hodgkin’s disease: short-term results of 2 randomized clinical trials. Cancer Res 26:1268–1276

    PubMed  CAS  Google Scholar 

  • Kinzie J, Hanks G, Maclean C, Kramer S (1983) Patterns of care study: Hodgkin’s disease relapse rate and adequacy of portals. Cancer 52:2223–2226

    PubMed  CAS  Google Scholar 

  • Klimm B, Eich HT, Haverkamp H et al. (2007) Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 18 (2):357–363

    PubMed  CAS  Google Scholar 

  • Kobe C, Dietlein M, Franklin J, et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112 (10):3989–3994

    PubMed  CAS  Google Scholar 

  • Kriz J, Bangard C, Haverkamp U, Bongartz R et al. (2012) Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group. Strahlenther Onkol. Aug;188(8):660–665

    Google Scholar 

  • Lagarde P, Eghballi H, Bonichon F, Mascarel ID, Chauvergne J, Haerni B (1988) Brief chemotherapy associated with extended field radiotherapy in Hodgkin’s disease. Long-term results in a series of 102 patients with clinical stages I-IIIA. Eur J Cancer Clin Oncol 24:1191–1198

    PubMed  CAS  Google Scholar 

  • Lee CKK, Aeppli DM, Bloomfield CD, Levitt SH (1987) Hodgkin’s disease: a reassessment of prognostic factors following modification of radiotherapy. Int J Radiat Oncol Biol Phys 13:983–991

    PubMed  CAS  Google Scholar 

  • Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelson T, Rosenberg SA (1989) Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin’s disease. J Clin Oncol 7:81–91

    PubMed  CAS  Google Scholar 

  • Levitt SH, Lee CKK (1983) Radical radiation therapy in the treatment of laparotomy staged Hodgkin’s disease patients. In: Amendola BE, Amendola MA (eds) Recent trends in radiation oncology and related fields. Elsevier, Amsterdam, pp 21–38

    Google Scholar 

  • Linch D, Winfield D, Goldstone A et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet 341:1051

    PubMed  CAS  Google Scholar 

  • Lipshultz SE, Colan SD, Gelber RD, Perez AA, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood (see comments). N Engl J Med 324:808–815

    PubMed  CAS  Google Scholar 

  • Lister T, Crowther D, Sutcliffe S (1989) Report of a Committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630

    PubMed  CAS  Google Scholar 

  • Loeffler M, Bosteanu O, Hasenclever D et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s disease Overview Study Group. J Clin Oncol 16:818–829

    PubMed  CAS  Google Scholar 

  • Loeffler M, Diehl V, Pfreundschuh M et al. (1997) Dose-response relationship of complimentary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin’s disease. J Clin Oncol 15:2275–2287

    PubMed  CAS  Google Scholar 

  • Longo D, Glatstein E, Duffey P et al. (1991) Radiation therapy versus combination chemotherapy in the treatment of earlystage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol 9:960–971

    Google Scholar 

  • Longo DL (1990) The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol 17:716–735

    PubMed  CAS  Google Scholar 

  • Longo DL, Young RC, DeVita VT (1982) Chemotherapy for Hodgkin’s disease. Cancer Treatm Rep 66:925–936

    CAS  Google Scholar 

  • Lukes RJ, Buttler JJ (1966) The pathology and nomenclature of Hodgkin’s disease. Cancer Res 26:1063–1081

    PubMed  CAS  Google Scholar 

  • Lukes RJ, Buttler JJ, Hicks EB (1966) Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer 19:317–344

    Google Scholar 

  • Macdonald DA, Ding K, Gospodarowicz MK et al. (2007) Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 18:1680–1684

    PubMed  CAS  Google Scholar 

  • MacLennan KA, Bennett MH, Tu A, Vaughan-Hudson B, Easterling MJ, Vaughan-Hudson G, Jelliffe AM (1989) Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. Cancer 64:1686–1693

    PubMed  CAS  Google Scholar 

  • Mattaei D, Kliem G, Döler W et al. (1993) Vergleichende Betrachtung von Paraaortalfeldern im Rahmen der Deutschen Hodgkin-Studie. Strahlentherapie Onkol 169:590–594

    Google Scholar 

  • Mauch P (1998) What is the role for adjuvant radiation therapy in advanced Hodgkin’s disease. J Clin Oncol 16:815–817

    PubMed  CAS  Google Scholar 

  • Mauch P, Goodman R, Hellman S (1978) The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 42:1039–1045

    PubMed  CAS  Google Scholar 

  • Mauch P, Larson D, Osteen R et al. (1990) Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 8:257

    PubMed  CAS  Google Scholar 

  • Mauch P, Tarbell N, Skarin A, Rosenthal D, Weinstein H (1987) Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 5:544–549

    PubMed  CAS  Google Scholar 

  • Mauch P, Tarbell N, Weinstein H et al. (1988) Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576–1583

    PubMed  CAS  Google Scholar 

  • Mauch PM, Kalish LA, Marcus KC et al. (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s diasease: long-term analysis of risk factors and outcome. Blood 87:3625–3632

    PubMed  CAS  Google Scholar 

  • Mauch PM, Kalish LA, Markus KC et al. (1995) Long term survival in Hodgkin’s disease: Relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1:33–42

    PubMed  CAS  Google Scholar 

  • Mefferd JM, Donaldson SS, Link MP (1989) Pediatric Hodgkin’s disease: Pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 16:679–685

    PubMed  CAS  Google Scholar 

  • Mendenhall NP, Cantor AB, Barre DM, Lynch JWL Jr, Million RR (1994) The role of prognostic factors in treatment selection for early-stage Hodgkin’s disease. Am J Clin Oncol 17:189–195

    PubMed  CAS  Google Scholar 

  • Meyer RM, Gospadorowicz MK, Connors JM et al. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634–4642

    PubMed  CAS  Google Scholar 

  • Miettinen M, Franssila KO, Saxen E (1983) Hodgkin’s disease, lymphocyte predominance nodular. Increased risk of subsequent non-Hodgkin’s lymphoma. Cancer 51:2293

    PubMed  CAS  Google Scholar 

  • Munker R, Hasenclever D, Bosteanu O, Hiller E, Diehl V (1995) Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. J Clin Oncol 13:403

    PubMed  CAS  Google Scholar 

  • Musshoff K, Boutis L (1967) Die Frage der Heilbarkeit der Lymphogranulomatose, beurteilt nach den Behandlungsergebnissen der Freiburger Medizinischen Klinik. Verh Dt Ges Inn Med 73:322–329

    CAS  Google Scholar 

  • Musshoff K, Boutis L (1968) Therapy results in Hodgkin’s disease. Cancer 21:1100–1113

    PubMed  CAS  Google Scholar 

  • Musshoff K, Weidkuhn V, Bammert J, Felker HU (1985 a) Diagnostik und Therapie der Hodgkin’schen Erkrankung in Freiburg im Breisgau 1964–1976. 1. Mitteilung: Ergebnisse des Gesamtkollektivs. Strahlentherapie 161:581–595

    PubMed  CAS  Google Scholar 

  • Musshoff K, Weidkuhn V, Bammert J, Felker HU (1985 b) Diagnostik und Therapie der Hodgkin’schen Erkrankung in Freiburg im Breisgau 1964–1976. 2. Mitteilung: Ergebnisse der Behandlungsperiode 1971–1976 im Vergleich zur Periode 1964–1971. Strahlentherapie 161:596–614

    PubMed  CAS  Google Scholar 

  • Naida JD, Eisbruch A, Schoeppel SL, Sandler HM, Turrisi AT, Lichter AS (1996) Analysis of localization errors in the definition of the mantle field using a beams eye view treatment planning system. Int J Radiat Oncol Biol Phys 35:377–382

    PubMed  CAS  Google Scholar 

  • Nissen N, Nordentoft A (1982) Radiotherapy versus combined modality treatment of stage I and II Hodgkin’s disease. Cancer Treat Rep 66:799–803

    PubMed  CAS  Google Scholar 

  • Nogová L, Reineke T, Josting A, et al. (2005) Lymphocyte-predominant and classical Hodgkin’s lymphoma–comparison of outcomes. Eur J Haematol 66 Suppl:106–110

    Google Scholar 

  • Nogová L, Reineke T, Eich HT, et al. (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16 :1683–1687

    PubMed  Google Scholar 

  • Noordijk E, Carde P, Hagenbeek A (1997) A combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease. Six-year results of the EORTC-GPMC controlled clinical trials “H7-VF” and “H7-U”. Int J Radiat Oncol Biol Phys 39:173 (abst)

    Google Scholar 

  • Noordijk E, Kluin-Nelemanns J (1997) Stage I or II Hodgkin’s disease: more chemotherapy and less irradiation. Ned Trijdschr Geneeskd 142:1281

    Google Scholar 

  • Noordijk EM, Carde P, Mandard AM et al. (1994) Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin’s disease. EORTC Lymphoma Cooperative Group and Pierre-et Marie-Curie. Ann Oncol 5 (Suppl 2):107–112

    PubMed  Google Scholar 

  • Nordentoft A (1972) Radiotherapy in 50 cases of Hodgkin’s disease in stages I and II. Report from the Lymphogranulomatosis Committee. Ugeskr Laeger 134:2383–2385

    Google Scholar 

  • Pavlovsky S, Maschio M, Santarelli MT et al. (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I/II Hodgkin’s disease. J Natl Cancer Inst 80:1466

    PubMed  CAS  Google Scholar 

  • Pavlovsky S, Schvartzman E, Lastiri F et al. (1997) Randomized trial of CVPP for three versus six cycles in favorable-prognosis untreated Hodgkin’s disease. J Clin Oncol 15:2652–2658

    PubMed  CAS  Google Scholar 

  • Peters MV (1966) Prophylactic treatment of adjacent areas in Hodgkin’s disease. Cancer Res 26:1232–1243

    PubMed  CAS  Google Scholar 

  • Peters MV (1950) A study in survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol 63:299–311

    Google Scholar 

  • Peters MV, Middlemiss K (1958) A study of Hodgkin’s disease treated by irradiation. Am J Roentgenol 79:114–121

    CAS  Google Scholar 

  • Podoloff DA (1996) Diffuse lung uptake of Ga-67 in treated lymphoma: Another milestone on the road to understanding. Radiology 199:318–320

    Google Scholar 

  • Press OW, Leblanc M, Lichter AS et al. (2001) Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 22:4238–4244

    Google Scholar 

  • Prosnitz LR, Curtis AM, Knowlton AH, Peters LM, Farber LR (1980) Supradiaphragmatic Hodgkin’s disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6:809–813

    PubMed  CAS  Google Scholar 

  • Prosnitz LR, Wu JJ, Yahalom J (1996) The case for adjuvant radiation therapy in advanced Hodgkin’s disease. Cancer Invest 14:361–370

    PubMed  CAS  Google Scholar 

  • Pusey W (1902) Cases of sarcoma and of Hodgkin’s disease treated by exposures to x-ray: a preliminary report. JAMA 38:166–169

    Google Scholar 

  • Radford JA, Crowther D, Rohariner AZS et al. (1995) Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol 13:2379

    PubMed  CAS  Google Scholar 

  • Raemaekers J, Burgers M, Henry-Amar M et al. (1997) Patients with stage III/IV Hodgkin’s disease in partial remission after MOPP/ABVD chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et Marie-Curie. Ann Oncol 8 (Suppl 1):111–114

    PubMed  Google Scholar 

  • Raemaekers J. (2010) EORTC/GELA/IIL randomized intergroup trial in early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with stages I/II Hodgkin’s lymphoma. Presented at the 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 24–26

    Google Scholar 

  • Reed D (1902) On the pathological changes in Hodgkin’s disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp rep 10:133

    Google Scholar 

  • Regula DP, Hoppe RT, Weiss LM (1988) Nodular and diffuse types of lymphocyte predominance Hodgkin’s disease. N Engl J Med 318:214

    Google Scholar 

  • Roach M, Brophy N, Cox R, Varghese A, Hoppe RT (1990) Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease. J Clin Oncol 8:623

    PubMed  Google Scholar 

  • Ron E, Lubin JH, Shore RE et al. (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259

    PubMed  CAS  Google Scholar 

  • Röntgen WG (1895) Über eine neue Art von Strahlen. Sitzungsberichte der physikalisch-medizinischen Gesellschaft zu Würzburg 30:132–141

    Google Scholar 

  • Rosenberg SA (1996) The management of Hodgkin’s disease: Half a century of change. Ann Oncol 7:555–560

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11:5

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Kaplan HS (1970) Hodgkin’s disease and other malignant lymphomas. Calif Med 113:23–38

    PubMed  CAS  Google Scholar 

  • Rosenthal SR (1936) Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis. Arch Pathol 21:628

    Google Scholar 

  • Rostock R, Giangreco A, Wharam M, Lenhard R, Siegelman SS, Order SE (1982) CT scan modification in the treatment of mediastinal Hodgkin’s disease. Cancer 49:2267–2275

    PubMed  CAS  Google Scholar 

  • Rubin P, Casarett G (1968) Clinical radiation pathology. WB Saunders, Philadelphia

    Google Scholar 

  • Rueffer U, Josting A, Franklin J et al. (2004) Non-Hodgkin’s lymphoma after primary Hodgkin’s disease in the German Hodgkin’s Lymphoma Study Group: incidence, treatment, and prognosis. Ann Oncol 15 (7): 1079–1085

    Google Scholar 

  • Sadural E (1995) Haematological malignancies during pregnancy. Clin Obstet Gynecol 38:535

    PubMed  CAS  Google Scholar 

  • Salloum E, Doria R, Schubert W et al. (1996) Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14:2435–2443

    PubMed  CAS  Google Scholar 

  • Santoro A (1997) Annual Conference of ECCO. Hamburg (abstr.)

    Google Scholar 

  • Santoro A, Bonadonna G, Valagussa P et al. (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27–37

    PubMed  CAS  Google Scholar 

  • Santoro A, Bonfante V, Viviani S et al. (1996) Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin’s disease (HD). Proc Am Soc Clin Oncol 15:415

    Google Scholar 

  • Santoro A, Viviani S, Villarreal C et al. (1986) Salvage therapy in Hodgkin’s disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70:343

    PubMed  CAS  Google Scholar 

  • Santoro A, Viviani S, Zucali R et al. (1983) Comparative results and toxicity of MOPP vs ABVD combined with radiotherapy (RT) in PS IIB, III (A, B) Hodgkin’s disease (HD). Annual Meeting American Society of Clinical Oncology, San Diego, CA

    Google Scholar 

  • Schewe K, Reavis J, Kun L, Cox J (1988) Total dose, fraction size, and tumor volume in the local control of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 15:25–28

    PubMed  CAS  Google Scholar 

  • Schmitz N, Sextro M, Pfistner B (1999) HDR-1: high-dose therapy (HDT) followed by hematopoetic stem cell tranplantation (HSCT) for relapsed chemosensitive Hodgkin’s disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 18 (Suppl 5):18

    Google Scholar 

  • Schmoll H (1982) Review of etoposide single-agent activity. Cancer Treatment Rev 9 (Suppl):21–30

    Google Scholar 

  • Schomberg PJ, Evans RG, O’Connel MJ et al. (1984) Prognostic significance of mediastinal mass in adult Hodgkin’s disease. Cancer 53:324–328

    PubMed  CAS  Google Scholar 

  • Schulz H, Rehwald U, Morschhauser F et al. (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111 (1):109–111

    PubMed  CAS  Google Scholar 

  • Senn N (1903) Therapeutical value of roentgen ray in treatment of pseudoleukemia. NY Med J 77:665–668

    Google Scholar 

  • Shahidi M, Kamangari N, Ashley S et al. (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5

    PubMed  Google Scholar 

  • Shore T, Nelson N, Weinerman B (1990) A meta-analysis of stages I and II Hodgkin’s disease. Cancer 65:1155–1160

    PubMed  CAS  Google Scholar 

  • Sienawski M, Franklin J, Nogova L et al. (2007) Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol. 25 (15):2000–2005

    Google Scholar 

  • Sommers R, Tubiana M, Henry-Amar M (1989) EORTC lymphoma cooperative group studies in clinical stage I-II Hodgkin’s disease 1963–1987. Rec Results Cancer Res 117:175–181

    Google Scholar 

  • Specht L (1996) Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol 6:146

    Google Scholar 

  • Specht L, Gray R, Clarke M, Peto R (1998) The influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin’s disease: a metaanalysis of 23 randomized trials involving 3888 patients. J Clin Oncol 16:830–843

    PubMed  CAS  Google Scholar 

  • Specht L, Nissen N (1989) Hodgkins disease and age. Eur J Haematol 43:127

    PubMed  CAS  Google Scholar 

  • Specht LK, Hasenclever D (1999) Prognostic factors of Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 295–326

    Google Scholar 

  • Stein H, Schwarting R, Dallenbach F, Dienemann D (1989) Immunology of Hodgkin and Reed-Sternberg cells. Recent Results Cancer Res 117:14–27

    PubMed  CAS  Google Scholar 

  • Sternberg C (1898) Über eine eigenartige unter dem Bilde der pseudoleukämie verlaufende Tuberkulose des lymphatischen Apparates. Ztschr Heilk 19:21

    Google Scholar 

  • Straus DJ, Myers L, Passe S (1980) The eight-drug/radiation therapy program (MOPP/ABVD/RT) for advanced Hodgkin’s disease – a follow-up report. Cancer 46:233–239

    PubMed  CAS  Google Scholar 

  • Straus DJ, Yahalom J, Gaynor J et al. (1992) Four cycles of chemotherapy and regional radiation therapy for clinical earlystage and intermediate-stage Hodgkin’s disease. Cancer 69:1052–1060

    PubMed  CAS  Google Scholar 

  • Sutcliffe S, Gospodarowicz M, Bergsagel D et al. (1985) Prognostic groups for management of localized Hodgkin’s disease. J Clin Oncol 3:393

    PubMed  CAS  Google Scholar 

  • Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, Lennan KAM (1992) Risk of second primary cancer after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br J Med 304:1137–1143

    CAS  Google Scholar 

  • Swerdlow AJ, Douglas AJ, Hudson V et al. (1993) Risk of second primary cancer after Hodgkin’s disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin’s disease and splenectomy. Br J Cancer 68:1006–1011

    PubMed  CAS  Google Scholar 

  • Tarbell N, Thompson L, Mauch P (1990) Thoracic irradiation in Hodgkin’s disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 18:275

    PubMed  CAS  Google Scholar 

  • Tesch H, Diehl V, Lathan B et al. (1998) Moderate dose escalation for advanced stage Hodgkin’s disease using bleomycin, etoposid, adriamycin, cyclophosphamide, vincristine, procarbacine and prednison scheme and adjuvant radiotherapy: A study of the German Hodgkin Lymphoma Study Group. Blood 92:4560

    PubMed  CAS  Google Scholar 

  • Thompson DE, Mabuchi K, Ron E et al. (1994) Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958–1987. Radiat Res 137:17. Published erratum appears in Radiat Res 139:129

    Google Scholar 

  • Torti FM, Portlock CS, Rosenberg SA, Kaplan HS (1981) Extralymphatic Hodgkin’s disease. Prognosis and response to therapy. Am J Med 70:487–492

    PubMed  CAS  Google Scholar 

  • Tubiana M, Henry-Amar M, Carde P (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73:47

    PubMed  CAS  Google Scholar 

  • Tubiana M, Henry-Amar M, Hayat M et al. (1984) Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 54:885–894

    PubMed  CAS  Google Scholar 

  • Tubiana M, Mathe G, Laugier A (1968) Current clinical trials in the radiotherapy of Hodgkin’s disease. Cancer Res 26:1277–1278

    Google Scholar 

  • Tucker M (1993) Second cancers following Hodgkin’s disease. Hematol Clin North Am 7:389

    CAS  Google Scholar 

  • Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 318:76

    PubMed  CAS  Google Scholar 

  • Tucker MA, Jones PH, Boice JD et al. (1991) Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 51:2885

    PubMed  CAS  Google Scholar 

  • Uematsu M, Tarbell NJ, Siver B et al. (1993) Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin’s disease in relapse after initial combination chemotherapy. Cancer 72:207

    PubMed  CAS  Google Scholar 

  • Valagussa P (1993) Second neoplasms following treatment of Hodgkin’s disease. Curr Opin Oncol 5:805

    PubMed  CAS  Google Scholar 

  • Van Leeuwen F, Sommers R, Taal B (1989) Increased risk of lung cancer, non-Hodgkin’s lymphoma and leukemia following Hodgkin’s disease. J Clin Oncol 7:1046

    PubMed  CAS  Google Scholar 

  • Van Leeuwen FE, Klokman WJ, Hagenbeck A et al. (1994) Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 13:312–325

    Google Scholar 

  • Van Leeuwen FE, Swerdlow AJ, Valagussa P (1999) Second Cancers after treatment of Hodgkin’s disease. In: Mauch PM, Armittage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 607–633

    Google Scholar 

  • Vaughan-Hudson B, Maclennan KA, Bennett MH, Easterling MJ, Hudson GV, Jelliffe AM (1987) Systemic disturbance in Hodgkin’s disease and its relation to histopathology and prognosis (BNLI report no. 30). Clin Radiol 38:257–261

    PubMed  CAS  Google Scholar 

  • Vijayakumar S (1992) What dose in Hodgkin’s disease? A review of dose-response data. Onkologie 15:190–196

    Google Scholar 

  • Vijayakumar S, Myrianthopoulos L (1992) An updated dose-response analysis in Hodgkin’s disease. Radiother Oncol 24:1–13

    PubMed  CAS  Google Scholar 

  • Vijayakumar S, Rosenberg I, Brandt T, Spelbrink D, Rubin S (1992) Quantification of doses to mediastinal lymph nodes in Hodgkin’s disease. Med Dosimetry 17:87–94

    CAS  Google Scholar 

  • Viviani S, Bonadonna G, Santoro A et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 14:1421

    PubMed  CAS  Google Scholar 

  • Westling P (1965) Studies of the prognosis in Hodgkin’s disease. Acta Radiol 245:5

    Google Scholar 

  • Wiernik P, Lichtenfeld D (1975) Combined modality therapy for localized Hodgkin’s disease. Oncology 32:208–213

    PubMed  CAS  Google Scholar 

  • Wilks S (1865) Case of enlargement of the lymphatic glands and spleen (or Hodgkin’s disease), with remarks. Guy’s Hosp Rep 11:56–67

    Google Scholar 

  • Wirth A, Corry J, Laidlaw C, Matthews J, Liew KH (1997) Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 39:599–607

    PubMed  CAS  Google Scholar 

  • Zietman AL, Linggood RM, Brookes AB, Convey K, Piro A (1991) Radiation therapy in the management of early stage Hodgkin’s disease. Cancer 68:1869

    PubMed  CAS  Google Scholar 

  • Zittoun R, Audebert A, Hoerni B et al. (1985) Extended versus involved field irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3:207–214

    PubMed  CAS  Google Scholar 

Zu Non-Hodgkin-Lymphome

  • Aviles A, Delgado S, Fernandez R et al. (2002) Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol 68:144–149

    PubMed  CAS  Google Scholar 

  • Aviles A, Delgado S, Nambo MJ et al. (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30:799–803

    PubMed  CAS  Google Scholar 

  • Bay JY, Gomez F, Sebban C et al. (1998) The International Prgnostic Index correlates to survival in patients withaggressive lymphoma in relapse. Analysis of the PARMA trial. Blood 92:3562–3568

    Google Scholar 

  • Besa PC, McLaughlin PW, Cox JD et al. (1995) Long term assesment of patterns of treatment failure and survival in patients with stage I and II follicular lymphoma. Cancer 75:2361–2367

    PubMed  CAS  Google Scholar 

  • Bhatia S, Arnold C, Paulino AC et al. (2002) Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 54:818–823

    PubMed  Google Scholar 

  • Bischof M, Zierhut D, Gutwein S et al. (2001) Die Venenverschlusskranheit nach infradiaphragmaler total lymphatischer Bestrahlung. Strahlenther Onkol 177:296–301

    PubMed  CAS  Google Scholar 

  • Bischof M, Karagiozidis M, Krempien R et al. (2007) Radiotherapy for orbital lymphoma: outcome and late effects. Strahlentherapie Onkologie 183:17–22

    Google Scholar 

  • Bolek TW, Moyses HM, Marcus RB Jr et al. (1999) Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 44:31–36

    PubMed  CAS  Google Scholar 

  • Bunn PA, Hoffmann SJ, Norris D et al. (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary Syndrome). Ann Internal Med 121:592–602

    Google Scholar 

  • Coiffier B, Lepage E, Briere J (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients. N Engl J Med 346:235–242

    PubMed  CAS  Google Scholar 

  • DeAngelis LM (1995) Current management of the primary central nervous system lymphoma. Oncology 9:63–71

    PubMed  CAS  Google Scholar 

  • De Angelis LM, Seiferheld W, Schold SC (2002) Radiation therapy oncology group study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: RTOG-study 93-10. J Clin Onc 20:4643–4648

    Google Scholar 

  • Esik O, Ikeda H, Mukai K et al. (1996) A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin’s lymphomas. Radiother Oncol. 38:13–18

    PubMed  CAS  Google Scholar 

  • Fitzpatrick PJ, Macko S. (1984) Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 10:333–340

    PubMed  CAS  Google Scholar 

  • Funk A, Hensley F, Krempien R et al. (2008) Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma. Eur J Dermatol 18:308–312

    PubMed  Google Scholar 

  • Galieni P, Polito E, Leccisotti A et al. (1997) Localized orbital lymphoma. Haematologica 82:436–439

    PubMed  CAS  Google Scholar 

  • Goffinet DR, Glatstein E, Fuks Z (1976) Abdominal irradiation in non-Hodgkin´s lymphoma. Cancer 37:2797

    PubMed  CAS  Google Scholar 

  • Haas RL, Poortmans P, de Jong D et al. (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphoma. J Clin Onc 21:2474–2480

    CAS  Google Scholar 

  • Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J (2000) Lymphoma classification from controversy to consensus: The R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 11:3–10

    PubMed  Google Scholar 

  • Held G, Schubert J, Rübe C et al. (2006) Fortschritte in der Behandlung der diffus-großzelligen Lymphome. Onkologe 12:619–627

    Google Scholar 

  • Hiddemann W, Unterhalt M, Wandt H (1999) Myeloablative radiochemotherapy followed by blood-stemcell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized trial of the GLSG. Blood 94 (Suppl.):610A

    Google Scholar 

  • Jones GW, Tadros A, Hodson DJ et al. (1994) Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 to 35 Gy. Int J Radiat Oncol Biol Phys 28:839–845

    PubMed  CAS  Google Scholar 

  • Koch P, Berdel WE, Willich N et al. (2001) Grading in marginal-zone lymphomas. J Clin Oncol 18:2788

    Google Scholar 

  • Koch P, Lehnert T, Willich N (2001) Gastrointestinale Lymphome. Onkologe 7:982–989

    Google Scholar 

  • Koch P, Valle F del, Berdel WE et al. (2001) Primary gastrointestinal non-Hodgkin´s lymphoma I: anatomical and histological distribution, clinical features and survival data of 371 patients registered in the German Multicenter Study (GIT NHL 01/ 92). J Clin Oncol 19:3861–3873

    PubMed  CAS  Google Scholar 

  • Korfel A, Weller M, Plasswilm L, Bamberg M, Thiel E (2001) Primäre ZNS-Lymphome des immunkompetenten Patienten. Onkologe 7:990–997

    Google Scholar 

  • Lawrence T, Urba W, Steinberg S et al. (1988) Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 14:417–424

    PubMed  CAS  Google Scholar 

  • Le QT, Eulau SM, George TI et al. (2002) Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 52:657–663

    PubMed  Google Scholar 

  • Levitt S, Bloomfield C, Fizzera G et al. (1980) Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer Treat Rep 64:175–177

    PubMed  CAS  Google Scholar 

  • MacManus MP, Bowie CA, Hoppe RT (1998) What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma? Int J Radiat Oncol Biol Phys 42:365–371

    CAS  Google Scholar 

  • Martinet S, Ozsahin M, Belkacemi Y et al. (2003) Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 55:892–898

    PubMed  Google Scholar 

  • Micaily B, Moser C, Vonderheid EC et al. (1990) The radiation therapy of early stage cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 18:1333–1339

    PubMed  CAS  Google Scholar 

  • Moser EC, Kluin-Nelemans HC, Carde P et al. (2006) Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin’s lymphoma. In J Radiat Oncol Biol Phys 66:1168–1177

    Google Scholar 

  • NHL, Lymphoma, pathologic, Classification, Project (1982) National cancer institute sponsored study of classification of Non-Hodgkin´s Lymphomas. Cancer 49:2112–2135

    Google Scholar 

  • O´Brien P, Roos D, Pratt G et al. (2000) Phase II multicenter study of brief single agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526

    Google Scholar 

  • Parsonett J, Hansen S, Rodriguez L (1994) Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330:1267–1271

    Google Scholar 

  • Pelloski CE, Wilder RB, Ha CS et al. (2001) Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiother Oncol 59:145–151

    PubMed  CAS  Google Scholar 

  • Pfreundschuh M, Trümper L, Osterborg A et al. (2006) CHOP-like chemotherapy plus Rituximab versus CHOP-like chemotherapy alone in young patients with good- prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391

    PubMed  CAS  Google Scholar 

  • Poortmanns PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. (2003) High-dose methotrexate-based chemotherapy followed by consolidation radiotherapy in non-AIDS-related primary central nervous system lymphoma: EORTC phase-II trail 20962. J Clin Onc 21:4483–4488

    Google Scholar 

  • Rappaport H (1966) Tumors of the hematopoietic system. In: Atlas of tumor pathology. Sect. II. Armed Forces Institute of Pathology, Washington,DC.

    Google Scholar 

  • Rockwood EJ, Zakov ZN, Bay JW (1984) Combined malignant lymphoma of the eye and CNS. J Neurosurg 61:369–373

    PubMed  CAS  Google Scholar 

  • Rübe C, Nguyen P, Klöss M et al. (2001) Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Haematol 80 (Suppl.):84–85

    Google Scholar 

  • Sack H, Hoederath M, Stuschke W et al. (1998) Strahlenbehandlung von follikulären Keimzentrumslymphomen. Strahlenther Onkol;174:178–185

    PubMed  CAS  Google Scholar 

  • Schelgel U, Korfel A, Thiel E et al. (2009) Primäre ZNS-Lymphome. Onkologe 15:211–221

    Google Scholar 

  • Schmidberger H, Hess CF, Rübe C (2001) Stellenwert der Strahlentherapie bei nodalen Non-Hodgkin Lymphomen in lokalen und fortgeschrittenen Stadien. Onkologe 7:960–968

    Google Scholar 

  • Stansfield AG, Diebold J, Noel H (1988) Kiel Classification. Lancet 1:292–293

    Google Scholar 

  • Stuschke M, Hoederath A, Sack H et al. (1997) Extended field and total central lymphatic radiotherapy for early stages nodal centroblastic-centrocytic lymphoma: results of a prospective multicenter study. Cancer 80:2273–2284

    PubMed  CAS  Google Scholar 

  • Sweet D, Kinzie J, Gaeke M et al. (1981) Survival of patients with localized diffuse histiocytic lymphoma. Blood 58:1218–1223

    PubMed  CAS  Google Scholar 

  • Shipp MA, Harrington DP et al. (1993) The International Non-Hodgkin´s Lymphoma prognostic factors project. A predictive model for aggressive Non-Hodgkin´s lympoma. N Engl J Med 329:987–949

    Google Scholar 

  • Welch K, Finkbeiner W, Alpers CE et al. (1984) Autopsy findings in the aquired immune deficiency syndrome. JAMA 1984 252:1152–1159

    PubMed  CAS  Google Scholar 

  • Wilder RB, Tucker SL, Chul S et al. (2001) Radiation therapy after partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 50:743–749

    PubMed  CAS  Google Scholar 

  • Wilder RB, Tucker SL, Chul S, Rodriguez MA et al. (2001) Dose response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 49:17–22

    PubMed  CAS  Google Scholar 

  • Woodman R, Shin K, Pineo G et al. (1985) Primary non-Hodgkin´s lymphoma of the brain: a review. Medicine 64:425–430

    PubMed  CAS  Google Scholar 

  • Ysebaert L, Truc G, Dalac S et al. (2004) Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58:1128–1134

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Radioonkologie und Strahlentherapie, Radiologische Klinik, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland

    M. Bischof

  2. Klinik für Strahlentherapie & Radioonkologie, Universitätsklinikum Münster, Albert-Schweizer-Campus 1 Gebäude 1, D-48149, Münster, Deutschland

    H.T. Eich

  3. Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Münster, Albert-Schweizer-Campus 1, 48149, Münster, Deutschland

    J. Kriz

Authors
  1. H.T. Eich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Kriz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bischof
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Heidelberg, Heidelberg, Germany

    Michael Wannenmacher

  2. Universitätsklinikum Mannheim, Mannheim, Germany

    Frederik Wenz

  3. Universitätsklinikum Heidelberg, Heidelberg, Germany

    Jürgen Debus

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Eich, H., Kriz, J., Bischof, M. (2013). Tumoren des lymphatischen Systems. In: Wannenmacher, M., Wenz, F., Debus, J. (eds) Strahlentherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88305-0_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-88305-0_30

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-88304-3

  • Online ISBN: 978-3-540-88305-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation